Abingdon Health Plc reported revenue results for the six months ended December 31, 2023. For the period, the company reported revenues more than doubled (+118%) to £2.4 million (first of 2022/3 £1.1 million). The growth has been driven by the company's contract service customer base across lateral flow research & development, technical transfer, manufacturing, analytical and regulatory services.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.75 GBX | 0.00% | +10.26% | -2.27% |
05-15 | Abingdon pregnancy self-tests now available under the Boots brand | AN |
05-15 | Abingdon Health Plans UK Launch of Saliva Pregnancy Test Product for Spring | MT |
1st Jan change | Capi. | |
---|---|---|
-2.27% | 42.75M | |
-5.27% | 12.32B | |
-3.86% | 8.07B | |
+33.66% | 5.52B | |
-7.35% | 4.21B | |
-55.63% | 2.99B | |
+13.62% | 2.73B | |
-3.65% | 2.43B | |
+30.67% | 2.29B | |
-4.31% | 1.89B |
- Stock Market
- Equities
- ABDX Stock
- News Abingdon Health Plc
- Abingdon Health Plc Reports Revenue Results for the Six Months Ended December 31, 2023